Research programme: antibacterials - Merck & Co

Drug Profile

Research programme: antibacterials - Merck & Co

Alternative Names: CNH365 396; CNH365.396; RX-100472

Latest Information Update: 23 Jan 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Trius Therapeutics
  • Developer Merck & Co
  • Class Amines; Benzimidazoles; Piperazines; Pyrimidines; Small molecules
  • Mechanism of Action Amino acyl tRNA synthetase inhibitors; DNA gyrase inhibitors; DNA topoisomerase inhibitors; DNA topoisomerase IV inhibitors; Enzyme inhibitors; Tetrahydrofolate dehydrogenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Anthrax; Bacterial infections

Most Recent Events

  • 21 Jan 2015 Cubist Pharmaceuticals has been acquired by Merck & Co
  • 11 Sep 2013 Trius Therapeutics has been acquired and merged into Cubist Pharmaceuticals
  • 12 Sep 2012 Preclinical antimicrobial data presented at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC-2012) ,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top